Arcus Biosciences (RCUS) Retained Earnings (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Retained Earnings of -$1.6 billion for Q1 2026, down 29.66% year-over-year from -$2.3 billion in Q1 2025, and down 16.97% quarter-over-quarter from -$1.4 billion in Q3 2025.
Arcus Biosciences (RCUS) Retained Earnings (2017 - 2026) Analysis & Trends
Arcus Biosciences' Retained Earnings history runs 10 years deep, the most recent figure standing at -$1.6 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 29.66% year-over-year to -$1.6 billion; the TTM figure through Mar 2026 stood at -$1.6 billion (down 29.66% YoY), while the FY2024 annual figure was -$1.1 billion, down 33.33% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.6 billion, down from -$1.4 billion in the prior quarter.
- The five-year high for Retained Earnings was $1.2 billion in Q3 2022, with the low at -$1.6 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$808.5 million (2023), against an average of -$553.2 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 313.33% in 2022, then slumped 138000.0% in 2025.
- Arcus Biosciences' Retained Earnings stood at -$542.0 million in 2022, then slumped by 56.64% to -$849.0 million in 2023, then plunged by 33.33% to -$1.1 billion in 2024, then decreased by 21.82% to -$1.4 billion in 2025, then retreated by 16.97% to -$1.6 billion in 2026.
- Business Quant data shows RCUS's Retained Earnings at -$1.6 billion in Q1 2026, -$1.4 billion in Q3 2025, and -$1.2 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -1.70 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.70 Bn |
| Mar 31, 2026 | -1.61 Bn |
| Sep 30, 2025 | -1.38 Bn |
| Jun 30, 2025 | -1.24 Bn |
| Mar 31, 2025 | -1.24 Bn |
| Dec 31, 2024 | -1.13 Bn |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | -946.00 Mn |
| Mar 31, 2024 | -853.00 Mn |
| Dec 31, 2023 | -849.00 Mn |
| Sep 30, 2023 | -768.00 Mn |
| Jun 30, 2023 | -4.00 Mn |
| Mar 31, 2023 | -622.00 Mn |
| Dec 31, 2022 | -542.00 Mn |
| Sep 30, 2022 | 1.18 Bn |
| Jun 30, 2022 | 1.16 Bn |
| Mar 31, 2022 | -4.66 Mn |
| Dec 31, 2021 | -1.00 Mn |
| Sep 30, 2021 | -554.72 Mn |
| Jun 30, 2021 | 1.08 Bn |